Pentavalent vaccine in Asian countries; Zoster vaccine safety and varicella vaccine safety in immunocompromised populations; Immunization during pregnancy; Yellow Fever vaccine safety during mass immunization campaigns in sub-Saharan Africa; Safety profile of Japanese encepahlitis vaccines; Update on human papillomavirus vaccines;Update on pandemic influenza vaccine (Pandemrix®) and narcolepsy.
Thiomersal in vaccines; Aluminium adjuvants; Vaccine safety in pregnancy and lactation; Use of influenza vaccines during pregnancy; Causality assessment of Adverse Events following Immunization; Core variables for AEFI monitoring.
Safety of influenza A(H1N1)pdm09 vaccines; Rotavirus vaccines and intussusception; Vaccine safety in pregnancy and lactation; Global network for postmarketing surveillance and AEFI monitoring; Implementing the Global Vaccine Safety Blueprint.
Safety profile of meningococcal A conjugate vaccine; Causes of adverse events following immunization; Information about rates of reactions to vaccines; Developing a global strategy for enhancing vaccine safety;
Safety of pandemic A (H1N1) influenza vaccines; Febrile seizures after seasonal influenza vaccine in Australia; Porcine circoviruses and rotavirus vaccines; Live attenuated hepatitis A vaccine; Updated safety of meningococcal A conjugate vaccine; Yellow fever vaccine and breastfeeding.
Safety of pandemic A (H1N1) influenza vaccines; Review of safety profile on meningococcal A conjugate vaccine from clinical trials; Use of BCG vaccine in HIV-infected infants; Strengthening global monitoring of adverse events following immunization.
Safety of experimental malaria vaccine RTS,S/AS01; Age of administration of rotavirus vaccines; Safety of human papillomavirus vaccines; Assessing the safety of novel influenza vaccines; Safety of measles vaccine in children infected with HIV.
Safety of yellow fever vaccine; Diphtheria-tetanus-pertussis vaccine and asthma; Non-specific effects of DTP vaccine on child mortality; Pregnancy outcomes after inadvertent immunization with rubella vaccine; Mitochondrial diseases and vaccination;Thiomersal; Report from subgroups.
Guillain-Barré syndrome and vaccination; Safety of immunization in immunocompromised individuals; Safety of yellow fever vaccines; Hepatitis B vaccination and rheumatoid arthritis; Safety of live 14-14-2 Japanese encephalitis vaccine; Safety of meningococcal B vaccines; Rotavirus vaccines and Kawasaki disease; Modus operandi of the committee and additional information.
Monitoring vaccine safety; Safety of vaccine formulations; Mumps vaccine virus strain repository; Safety of BCG vaccines; Safety of human papillomavirus vaccine; Update on Menactra® and Guillain-Barré syndrome; Safety of rotavirus vaccines; Influenza vaccines: update; Modus operandi of the Committee and additional information.
Monitoring vaccine safety; Report of the WHO Expert Committee on Biological Standardization; Safety of vaccine formulations; Vaccinating adolescents and young adults: problems with coincidental pathologies and safety assessments; Safety of mumps vaccine strains; Safety of BCG vaccine in HIV-infected children; Update on Menactra® and Guillain-Barré syndrome; Pandemic influenza vaccines; Safety of Japanese encephalitis vaccination in India; Safety of pneumococcal conjugate vaccine.
Vaccine safety monitoring and the WHO Programme for International Drug Monitoring; Post-marketing surveillance of rotavirus vaccines; Safety of squalene; Immunogenic overload; Safety of pandemic influenza vaccines; Safety issues of varicella vaccines; Modus operandi of the Committee and additional information
Vaccine Safety Net; Safety issues associated with pandemic influenza vaccines; Safety of adjuvants; Rotavirus vaccine safety; Subacute sclerosing panencephalitis and measles vaccination; Chronic fatigue syndrome and hepatitis B vaccination; Conjugate meningococcal vaccine and Guillain-Barré Syndrome; Modus operandi of the Committee.
Mouse brain-derived Japanese encephalitis vaccine; Safety of SA 14-14-2 Japanese encephalitis vaccine; Isoniazid resistance of bacille Calmette-Guérin strains; International drug monitoring; Thiomersal; Safety of hexavalent vaccines; Subacute sclerosing panencephalitis and measles vaccination; National regulatory authorities planning workshops.
Safety of adjuvants; Thiomersal: neurobehavioural studies on animal models; Safety of residual cellular DNA in vaccines; Transmissible spongiform encephalopathy; Potential risk of vaccines produced on yeast; Safety of hexavalent vaccines; Yellow fever; Vaccine Safety Net.
Intranasal influenza virus vaccine; Influenzae vaccines and neurological complications; Influenza vaccination of women during pregnancy; Nonspecific effects of childhood immunization; Safety issues in the poliomyelitis eradication campaign; International reference laboratory for mumps virus isolates; Yellow fever vaccine safety; BCG immunization in HIV-positive subjects; Safety of smallpox vaccination; Switch from rubella vaccine to mumps, measles and rubella vaccine; Aluminium-containing vaccines and macrophagic myofasciitis.
Safety of thiomersal-containing vaccines; Hepatitis B vaccine and leukaemia; Hepatitis B vaccine and multiple sclerosis; Aluminium-containing vaccines and macrophagic myofasciitis; Bell palsy following intranasal vaccination; Potential adverse impact of routine vaccination on child survival